Compare Medtronic PLC (MDT) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Banco Santander SA — how do they compare? Medtronic PLC trades at $82.85 (market cap $106.61B), while Banco Santander SA trades at $13.51 (market cap $191.46B). The key difference: Banco Santander SA is the larger of the two by market cap, and Medtronic PLC pays the higher dividend (3.46%). Which is the better fit depends on your goals.
| MDT | SAN | |
|---|---|---|
Market Cap | $106.61B | $191.46B |
Sector | Health | Financials |
52-Week High | $105.35 | $14.37 |
52-Week Low | $73.75 | $8.40 |
Enterprise Value | $125.36B | — |
Dividend Yield | 3.46% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
Banco Santander (SAN) trades at $13.31, down 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported Q1 2026 EPS of $0.41, beating expectations, but missed in prior quarters. Revenue for 2025 was $60.02B with a net income margin of 26.72%. Recent news highlights Santander's AI initiatives, acquisition of Webster Bank, and becoming Spain's most valuable company. Cash flow trends show operational challenges, with net cash flow negative in recent years.
Outlook is cautiously optimistic with a 64% analyst buy rating, targeting efficiency gains and AI-driven value. Risks include regulatory probes, declining cash flows, and high debt levels. The stock offers a dividend yield with the recent $0.15 payout, but investors should weigh operational improvements against financial volatility and macroeconomic pressures in the banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
